Soleno Therapeutics Inc (NASDAQ:SLNO) major shareholder Bioasia Mangement Llc sold 90,724 shares of the stock in a transaction on Monday, May 20th. The shares were sold at an average price of $1.93, for a total value of $175,097.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
NASDAQ:SLNO traded down $0.11 during trading hours on Friday, hitting $2.73. The company had a trading volume of 62,133 shares, compared to its average volume of 897,954. The stock has a market cap of $86.75 million, a P/E ratio of -4.20 and a beta of 2.52. Soleno Therapeutics Inc has a 1 year low of $1.11 and a 1 year high of $5.07.
Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Monday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.07. Analysts predict that Soleno Therapeutics Inc will post -0.77 EPS for the current year.
Separately, Zacks Investment Research raised Soleno Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research note on Saturday, May 18th.
Large investors have recently modified their holdings of the business. Virtu Financial LLC purchased a new stake in Soleno Therapeutics in the 1st quarter valued at $72,000. Fosun International Ltd purchased a new position in shares of Soleno Therapeutics during the 4th quarter worth $294,000. Trellus Management Company LLC grew its holdings in shares of Soleno Therapeutics by 10.8% during the 4th quarter. Trellus Management Company LLC now owns 169,380 shares of the company’s stock worth $290,000 after purchasing an additional 16,551 shares during the period. Vanguard Group Inc grew its holdings in shares of Soleno Therapeutics by 30.1% during the 3rd quarter. Vanguard Group Inc now owns 66,075 shares of the company’s stock worth $143,000 after purchasing an additional 15,281 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of Soleno Therapeutics during the 1st quarter worth $131,000. Institutional investors own 46.08% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Sundance Herald and is owned by of Sundance Herald. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://sundanceherald.com/2019/06/14/bioasia-mangement-llc-sells-90724-shares-of-soleno-therapeutics-inc-slno-stock.html.
Soleno Therapeutics Company Profile
Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc and changed its name to Soleno Therapeutics, Inc in May 2017.
Featured Story: What are defining characteristics of a correction?
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.